White House Partners with Eli Lilly, Novo Nordisk to Offer Discounted GLP-1 Drugs via TrumpRx

Under the new agreement, Novo Nordisk’s Ozempic and Wegovy will drop from around $1,000 and $1,350 per month to $350 when purchased through TrumpRx.

The White House has announced new agreements with Eli Lilly and Company and Novo Nordisk to make several GLP-1 drugs available at significantly reduced prices through the government’s digital prescription marketplace, TrumpRx.

TrumpRx, launched in September, allows consumers to purchase medications directly through the government at discounted rates, bypassing insurance channels. Under the new agreement, Novo Nordisk’s Ozempic and Wegovy will drop from around $1,000 and $1,350 per month to $350 when purchased through TrumpRx.

Eli Lilly’s Zepbound and orforglipron—pending U.S. Food and Drug Administration (FDA) approval—will decrease from around $1,086 per month to an average of $346. Zepbound (tirzepatide) is an FDA-approved multi-dose pen for obesity and sleep apnea, while orforglipron is Lilly’s once-daily obesity pill awaiting approval.

“Starting as early as April 1, 2026, Medicare beneficiaries will pay no more than $50 per month for Zepbound (tirzepatide), available in a multi-dose pen, and for orforglipron, Lilly's convenient once-daily obesity pill, provided both receive approval from the U.S. Food and Drug Administration (FDA). States will also have the ability to expand access to Zepbound and orforglipron through Medicaid,” Lilly said in a statement.

Additional discounts include Eli Lilly’s migraine medication Emgality, priced at $299 per pen (down from $443), and diabetes medication Trulicity, at $389 per month (down from $598). Novo Nordisk will also make its insulin products, including NovoLog and Tresiba, available for $35 per monthly supply.

If Novo Nordisk’s Wegovy pill or other oral GLP-1 drugs from either company receive FDA approval, initial doses will be available through TrumpRx for $150 per month.

“The agreement also provides that Eli Lilly and Novo Nordisk will guarantee MFN [most-favored nation] prices on all new medicines that they bring to market, repatriate increased foreign revenue on existing products, and provide every State Medicaid program in the country access to MFN drug prices on their products,” the White House said.

Both companies also announced expanded U.S. manufacturing investments. Novo Nordisk committed an additional $10 billion to strengthen its domestic operations, including producing the Wegovy tablet entirely in the U.S.. In comparison, Eli Lilly pledged at least $27 billion toward new U.S. manufacturing facilities.

The Trump administration had earlier launched TrumpRx with Pfizer in September to lower drug prices on several products, including Eucrisa, Xeljanz, and Zavzpret. Cigna and CVS Health later joined the initiative to distribute fertility treatments through the platform beginning January 2026.

Stay tuned for more such updates on Digital Health News